Agile Therapeutics (NASDAQ:AGRX) Research Coverage Started at started coverage on shares of Agile Therapeutics (NASDAQ:AGRXFree Report) in a research note released on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reissued a hold rating on shares of Agile Therapeutics in a research report on Monday, March 18th.

Get Our Latest Stock Analysis on AGRX

Agile Therapeutics Stock Performance

Shares of NASDAQ:AGRX opened at $0.36 on Thursday. Agile Therapeutics has a 52 week low of $0.20 and a 52 week high of $4.06. The company’s 50 day moving average is $0.38 and its two-hundred day moving average is $1.12. The company has a market cap of $2.48 million, a PE ratio of -0.10 and a beta of 1.25.

Agile Therapeutics (NASDAQ:AGRXGet Free Report) last posted its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter. The company had revenue of $5.72 million during the quarter.

Institutional Investors Weigh In On Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC lifted its position in shares of Agile Therapeutics, Inc. (NASDAQ:AGRXFree Report) by 10.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the period. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent reporting period. 10.92% of the stock is owned by hedge funds and other institutional investors.

About Agile Therapeutics

(Get Free Report)

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

See Also

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.